EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.
The goal of adjuvant anti-cancer therapies is cure with limited or no side effects, in particular long-term side effects with negative impact on quality of life. In the palliative setting disease control, quality of life and overall survival are important end points. Partly due to improvements in treatment, the population of cancer survivors is large and growing. However, anti-cancer drug-related cardiotoxicity (ADRC) is the leading cause of treatment-associated mortality in cancer survivors. It is one of the most common post-treatment problems among 5- to 10-year survivors of adult cancer. This is particularly true for breast cancer, the most common cancer in women. The EACVI/HFA COT registry is designed for comprehensive data collection and evaluation of the current European practice in terms of diagnosis and management of ADRC in breast cancer patients. The COT registry will be carried out in two continuing phases, the pilot study phase involving 13 countries followed by the long-term registry in which all the 56 ESC countries will be invited to participate. With the COT registry, several critical information will be obtained: on predisposing factors for the development of ADRC, the rate of subclinical LV dysfunction and its transition to overt heart failure, the clinical impact and outcome of ADRC.
University of Liège Hospital, GIGA Cardiovascular Science, Heart Valve Clinic, Imaging Cardiology, Belgium and GVM Care and Research, E.S. Health Science Foundation, Lugo (RA), Italy plancellotti@chu.ulg.ac.be.
Patrizio
P
Lancellotti
Department of Innovative Clinical Trials, University Medical Center Göttingen (UMG), Göttingen, Germany.
Stefan D
SD
Anker
Cardiologie, CHU Rennes and LTSI-INSERM U 1099, Université Rennes 1, Rennes, France.
Erwan
E
Donal
Department of Cardiology, Oslo University Hospital, Rikshospitalet and University of Oslo, Oslo, Norway Centre of Cardiological Innovation, Oslo, Norway.
Thor
T
Edvardsen
University of Medicine and Pharmacy 'Carol Davila'-Euroecolab, 'Prof. Dr C. C. Iliescu' Institute of Cardiovascular Diseases, Bucharest, Romania.
Bogdan A
BA
Popescu
Heart Failure Unit, Department of Cardiology, University Hospital 'Attikon', Athens, Greece.
Dimitrios
D
Farmakis
Heart Failure Unit, Department of Cardiology, University Hospital 'Attikon', Athens, Greece.
Gerasimos
G
Filippatos
Aix-Marseille Université, Marseille 13284, France Department of Cardiology, La Timone Hospital, 13005 Marseille, France.
Gilbert
G
Habib
ANMCO Research Center, Florence, Italy EORP Team, European Society of Cardiology, Sophia Antipolis, France.
Aldo P
AP
Maggioni
Medical Oncology, CHU Sart Tilman Liege and Liege University, Liege, Belgium.
Guy
G
Jerusalem
Department of Advanced Biomedical Sciences, Federico II University Hospital, Naples, Italy.
Maurizio
M
Galderisi
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D066126:Cardiotoxicity / Q000453:epidemiology / Q000209:etiology*; D054715:Cardiotoxins / Q000009:adverse effects*; D004347:Drug Interactions; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D011446:Prospective Studies; D011788:Quality of Life; D012042:Registries; D012107:Research Design; D012307:Risk Factors; D012955:Societies, Medical
D000970:Antineoplastic Agents; D054715:Cardiotoxins
biomarkers; breast cancer; cardiac toxicity; chemotherapy; left ventricular function